Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Intrahepatic cholangiocarcinoma: search for novel translational clinicopathologic and molecular biomarkers to predict early recurrence after curative surgery

EF 2021-22

Résumé
Intrahepatic cholangiocarcinoma (iCCA) is a type of bile duct cancer located inside the liver. iCCA is the second most common cause of liver cancers and only 10% of those who are diagnosed with this cancer survive past five years. The main challenge in treating iCCA is its high recurrence rate despite complete removal of the tumor. Harvesting circulating tumor DNA (ctDNA) or markers of inflammation from blood directly and studying them may be able to provide a solution to these issues. ctDNA are DNA fragments released in the blood stream from the tumor cells undergoing natural cell death. ctDNA is hypothesized to carry the same genetic altercations of the main tumor, however there are very few data available for this application. The same is true for blood derived systemic inflammatory biomarkers, like the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammatory index (SII). These ratios are easily obtainable from basic blood lab tests and could serve us in building tools to predict early cancer recurrence. Accurately predicting early cancer recurrence is important as it might save patients from undergoing major surgery, and instead receive additional treatments like chemotherapy to treat the whole body first from potential cancer spread. My research proposal seeks to study adult patients who undergo surgery for iCCA cure and (1) summarize all evidence on factors that predict early recurrence of iCCA; (2) define when is early and test whether systemic inflammatory biomarkers (NLR, PLR, SII) are a predictor for early recurrence; (3) assess whether ctDNA in the blood is a predictor for early recurrence and whether the mutations ctDNA in blood are representative of the resected primary tumor mutations. Findings from this study will be integral for guiding additional treatment strategies in patients with iCCA who are preparing to undergo surgery but are at high risk for early recurrence of the cancer.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
458302
Name
Choi Woo Jin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Intrahepatic cholangiocarcinoma: search for novel translational clinicopathologic and molecular biomarkers to predict early recurrence after curative surgery
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Bile Duct Cancer; Cholangiocarcinoma; Ctdna; Recurrence; Surgery
Abstract
Intrahepatic cholangiocarcinoma (iCCA) is a type of bile duct cancer located inside the liver. iCCA is the second most common cause of liver cancers and only 10% of those who are diagnosed with this cancer survive past five years. The main challenge in treating iCCA is its high recurrence rate despite complete removal of the tumor. Harvesting circulating tumor DNA (ctDNA) or markers of inflammation from blood directly and studying them may be able to provide a solution to these issues. ctDNA are DNA fragments released in the blood stream from the tumor cells undergoing natural cell death. ctDNA is hypothesized to carry the same genetic altercations of the main tumor, however there are very few data available for this application. The same is true for blood derived systemic inflammatory biomarkers, like the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammatory index (SII). These ratios are easily obtainable from basic blood lab tests and could serve us in building tools to predict early cancer recurrence. Accurately predicting early cancer recurrence is important as it might save patients from undergoing major surgery, and instead receive additional treatments like chemotherapy to treat the whole body first from potential cancer spread. My research proposal seeks to study adult patients who undergo surgery for iCCA cure and (1) summarize all evidence on factors that predict early recurrence of iCCA; (2) define when is early and test whether systemic inflammatory biomarkers (NLR, PLR, SII) are a predictor for early recurrence; (3) assess whether ctDNA in the blood is a predictor for early recurrence and whether the mutations ctDNA in blood are representative of the resected primary tumor mutations. Findings from this study will be integral for guiding additional treatment strategies in patients with iCCA who are preparing to undergo surgery but are at high risk for early recurrence of the cancer.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Choi, Woo Jin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~